Home>Topics>Stocks>Exact Sciences

Exact Sciences EXAS

  1. All
  2. Commentary
  3. Headlines
    1. EXACT Sciences' ( EXAS ) CEO Kevin Conroy on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Tue, 22 Jul 2014

      EXACT Sciences Corporation (NASDAQ: EXAS ) Q2 2014 Earnings Conference Call July 22, 2014 10:00 AM ET ..... Presentation Operator Good day, ladies and gentlemen, welcome to the Exact Sciences Second Quarter 2014 Earnings Conference Call. At this time

    2. More on Exact Sciences Q2 results

      Headlines

      Tue, 22 Jul 2014

      Exact Sciences (NASDAQ: EXAS ) Q2 results : Revenues: $0; R&D Expense: $7.2M (+11.1%); SG&A Expense: $12.4M (+78.9%); Operating

    3. Exact Sciences EPS in-line

      Headlines

      Tue, 22 Jul 2014

      Exact Sciences (NASDAQ: EXAS ): Q2 EPS of -$0.24 in-line. Press Release Post your comment!

    4. Notable earnings before Tuesday's open

      Headlines

      Mon, 21 Jul 2014

      ABG , AMTD , AOS , ARMH , ATI , BTU , CIT , CMCSA , CNC , COL , CS , CSL , DD , DFRG , DPZ , EDU , EXAS , FMER , GCI , HOG , HUB.B , IR , KMB , KO , LMT , LPT , LXK , MCD , MJN , MO , MOSY , NEOG , OMC , PII , PLD , RESI , RF , SAH

    5. From Barron’s, March 31, 2014 (Part 2)

      Commentary

      Sat, 29 Mar 2014

      ancillary-benefit suppliers MET, UNM ; PBMs CVS, ESRX ; managed-care providers AET, UNH, CI ; pg 17]; Exact Sciences [ EXAS ; impending FDA approval of its colon cancer screening test; pg 19]; REITs with DC office exposure [ BDN

    6. Connecting the DOTs: The Role of North America’s ‘Emerging Markets’ in Achieving Energy Independence

      Headlines

      Fri, 18 Oct 2013

      North Dakota and Western Canada should grow 10% per year over the next 3 years. In our opinion, North D akota, O klahoma and T exas are critical states from a production, pipeline route, storage and end-market consumption perspective. We believe these states

    7. From Barron’s, October 8, 2012 (Part 2)

      Commentary

      Sat, 6 Oct 2012

      favorable trials of muscular dystrophy drug; pg 18); Viacom ( VIA/VIAB ; pg 21); Brink’s ( BCO ; pg 22); Exact Sciences ( EXAS ; DNA-based Cologuard test trials appear promising; pg 25); Walgreen ( WAG ; 5-yr valuation low; pg 34

    « Prev123Next »
    Content Partners